Tcelna™ is being developed as a first line treatment for Multiple Sclerosis (MS). Opexa is currently conducting a Phase IIb clinical trial of Tcelna in Secondary Progressive MS (SP-MS) patients and partnering discussions are continuing in parallel.

Should you be interested in discussing possible partnering opportunities for Opexa's lead therapy Tcelna™, please contact us at:


Phone: 281.775.0600